Galcanezumab for the prevention of migraine

Lindsay M. Frerichs; Deborah I. Friedman

doi:10.2217/pmt-2020-0030

Galcanezumab for the prevention of migraine

Lindsay M. Frerichs, Deborah I. Friedman

Department of Neurology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.

Original language	English
Pages (from-to)	101-112
Number of pages	12
Journal	Pain Management
Volume	11
Issue number	2
DOIs	https://doi.org/10.2217/pmt-2020-0030
State	Published - Mar 2021

Keywords

CGRP monoclonal antibody
galcanezumab
headache
migraine
prevention
treatment

Access to Document

10.2217/pmt-2020-0030

Cite this

@article{bfba0adbe61948ff91a3401141b2fe98,

title = "Galcanezumab for the prevention of migraine",

abstract = "Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.",

keywords = "CGRP monoclonal antibody, galcanezumab, headache, migraine, prevention, treatment",

author = "Frerichs, {Lindsay M.} and Friedman, {Deborah I.}",

year = "2021",

month = mar,

doi = "10.2217/pmt-2020-0030",

language = "English",

volume = "11",

pages = "101--112",

journal = "Pain Management",

issn = "1758-1869",

number = "2",

}

TY - JOUR

T1 - Galcanezumab for the prevention of migraine

AU - Frerichs, Lindsay M.

AU - Friedman, Deborah I.

PY - 2021/3

Y1 - 2021/3

N2 - Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.

AB - Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.

KW - CGRP monoclonal antibody

KW - galcanezumab

KW - headache

KW - migraine

KW - prevention

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85124022844&partnerID=8YFLogxK

U2 - 10.2217/pmt-2020-0030

DO - 10.2217/pmt-2020-0030

M3 - Article

C2 - 33291980

AN - SCOPUS:85124022844

SN - 1758-1869

VL - 11

SP - 101

EP - 112

JO - Pain Management

JF - Pain Management

IS - 2

ER -

Galcanezumab for the prevention of migraine

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this